PlainRecalls
FDA Drug Moderate Class II Terminated

PHENOBARBITAL Sodium Injection, USP, 130 mg/mL, packaged as a) 25 x 1 mL Vials per box (NDC 42494-416-25) and b) 3 x 1mL Vials per box (NDC 42494-416-03), Rx only, Manufactured for Cameron Pharmaceuticals, LLC.

Reported: April 13, 2022 Initiated: March 14, 2022 #D-0744-2022

Product Description

PHENOBARBITAL Sodium Injection, USP, 130 mg/mL, packaged as a) 25 x 1 mL Vials per box (NDC 42494-416-25) and b) 3 x 1mL Vials per box (NDC 42494-416-03), Rx only, Manufactured for Cameron Pharmaceuticals, LLC.

Reason for Recall

Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended to be sterile.

Details

Units Affected
a) 18,531 boxes; b) 4,492 boxes
Distribution
Nationwide in the U.S.A
Location
San Diego, CA

Frequently Asked Questions

What product was recalled?
PHENOBARBITAL Sodium Injection, USP, 130 mg/mL, packaged as a) 25 x 1 mL Vials per box (NDC 42494-416-25) and b) 3 x 1mL Vials per box (NDC 42494-416-03), Rx only, Manufactured for Cameron Pharmaceuticals, LLC.. Recalled by Vitae Enim Vitae Scientific, Inc.. Units affected: a) 18,531 boxes; b) 4,492 boxes.
Why was this product recalled?
Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended to be sterile.
Which agency issued this recall?
This recall was issued by the FDA Drug on April 13, 2022. Severity: Moderate. Recall number: D-0744-2022.